Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dipyridamole trials in stroke prevention

H C Diener1

  • 1Department of Neurology, University of Essen, Germany.

Neurology
|September 23, 1998
PubMed
Summary

Combining aspirin with dipyridamole (DP) significantly enhances stroke risk reduction compared to aspirin alone. This combination therapy offers a more effective strategy for preventing strokes in at-risk individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Placebo Response in Acute and Prophylactic Treatment of Migraine: A Systematic Review and Meta-Analysis Covering 36 Years of Research.

Neurologic clinics·2025
Same author

[Diagnosis and treatment of acute ischemic insults].

Herz·2021
Same author

European Academy of Neurology guideline on the management of medication-overuse headache.

European journal of neurology·2020
Same author

MMW Fortschritte der Medizin·2018
Same author

Preventing dementia beyond treating hypertension.

European heart journal·2018
Same author

MMW Fortschritte der Medizin·2018

Area of Science:

  • Neurology
  • Cardiology
  • Pharmacology

Background:

  • Previous studies on aspirin combined with dipyridamole (DP) for stroke prevention yielded inconclusive results.
  • Early trials lacked the statistical power to demonstrate significant benefits of combination therapy over aspirin monotherapy.

Purpose of the Study:

  • To evaluate the efficacy of aspirin plus dipyridamole (DP) compared to aspirin alone in stroke prevention.
  • To determine if combination antiplatelet therapy offers additive benefits.

Main Methods:

  • The European Stroke Prevention Study 2 (ESPS-2) randomized 6,602 patients into four groups: aspirin plus sustained-release DP, aspirin alone, DP alone, or placebo.
  • Patients received aspirin (50 mg daily) and/or sustained-release DP (400 mg daily).

Main Results:

  • Aspirin plus sustained-release DP demonstrated a significantly greater reduction in stroke risk (37% reduction) compared to aspirin alone (18.1% reduction).
  • The combination therapy more than doubled the risk reduction achieved with aspirin monotherapy.
  • The effects of aspirin and DP appeared to be additive.

Conclusions:

  • Combination therapy with low-dose aspirin and sustained-release dipyridamole is a more effective strategy for stroke prevention than aspirin alone.
  • This regimen offers significant additive benefits in reducing stroke risk.

Related Experiment Videos